(Total Views: 575)
Posted On: 03/25/2021 7:53:31 AM
Post# of 154137
Awesome, Watch This Space:
https://covid-vaccine.canada.ca/leronlimab/product-details
Have to click "List of Applications" to see Leronlimab, didn't catch that at first.. it's generally a good list to be on. Notably absent is any offering from Relief...
https://covid-vaccine.canada.ca/
Data on Favipiravir has been pretty conflicting, and Colchicine is probably DOA. LLY and REGN MABs will probably be approved, even as their efficacy against variants weakens. NVAX as well..
keep an eye on B1.351, conveniently no mention of P.1
https://covid-vaccine.canada.ca/leronlimab/product-details
Have to click "List of Applications" to see Leronlimab, didn't catch that at first.. it's generally a good list to be on. Notably absent is any offering from Relief...
https://covid-vaccine.canada.ca/
Data on Favipiravir has been pretty conflicting, and Colchicine is probably DOA. LLY and REGN MABs will probably be approved, even as their efficacy against variants weakens. NVAX as well..
Quote:
Novavax Inc. has revealed that in a Phase III trial its NVX–CoV2373 vaccine candidate was 86.3 percent effective against the B.1.1.7 SARS-CoV-2 variant.
Additionally, the company reported that the final efficacy in its Phase IIb trial taking place in South Africa was 55.4 percent among the HIV-negative trial participants. The majority of infections in this region are B1.351 escape variants. Across both trials, NVX-CoV2373 demonstrated 100 percent protection against severe disease, including all hospitalisation and death.
keep an eye on B1.351, conveniently no mention of P.1
(6)
(0)
